Back

γδ T cells are the prime anti-tumoral T cells in pediatric neuroblastoma

Castenmiller, S. M.; Borst, A. L.; Wardak, L.; Molenaar, J. J.; Papadopoulou, M.; de Krijger, R. R.; van der Steeg, A. F. W.; Vermijlen, D.; de Groot, R.; Wienke, J. M.; Wolkers, M. C.

2025-01-26 cancer biology
10.1101/2025.01.23.634553 bioRxiv
Show abstract

High-risk pediatric neuroblastoma patients have a dismal survival rate despite intensive treatment regimens. New treatment options are thus required. Even though HLA expression in neuroblastoma is low and immune cell infiltrates are limited, the presence of tumor infiltrating lymphocytes (TILs) is indicative for better patient survival. Here, we show that most tumor lesions contain viable immune cell infiltrates after induction chemotherapy, with high percentages of CD3+ T cells. We therefore expanded the TILs and tested their anti-tumoral activity. With sufficient starting material, TIL expansion was as efficient as for adult solid tumors. However, whereas TIL products from adult tumors almost exclusively contained {beta} T cells, in neuroblastoma-derived TILs, {gamma}{delta} T cells expanded with similar efficacy as {beta} T cells. Importantly, the anti-tumor responses in response to autologous tumor digest primarily originated from (V{delta}1- and V{delta}3-expressing) {gamma}{delta} T cells, and not from {beta} T cells. In conclusion, this finding creates a window of opportunity for immunotherapy for neuroblastoma patients, with {gamma}{delta} T cells as potential prime responders.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Cancers
200 papers in training set
Top 0.2%
14.3%
2
OncoImmunology
22 papers in training set
Top 0.1%
12.3%
3
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 0.2%
6.4%
4
Scientific Reports
3102 papers in training set
Top 24%
4.8%
5
eLife
5422 papers in training set
Top 29%
3.1%
6
Cells
232 papers in training set
Top 1%
2.6%
7
Frontiers in Oncology
95 papers in training set
Top 2%
2.6%
8
PLOS ONE
4510 papers in training set
Top 45%
2.6%
9
Frontiers in Immunology
586 papers in training set
Top 3%
2.1%
50% of probability mass above
10
Cancer Immunology, Immunotherapy
11 papers in training set
Top 0.1%
1.8%
11
Neuro-Oncology
30 papers in training set
Top 0.4%
1.7%
12
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 4%
1.7%
13
EMBO Molecular Medicine
85 papers in training set
Top 2%
1.7%
14
Cell Reports Medicine
140 papers in training set
Top 4%
1.7%
15
Molecular Therapy
71 papers in training set
Top 2%
1.7%
16
Molecular Therapy - Methods & Clinical Development
38 papers in training set
Top 0.3%
1.5%
17
Antiviral Research
49 papers in training set
Top 0.2%
1.5%
18
Neoplasia
22 papers in training set
Top 0.3%
1.3%
19
Molecular Oncology
50 papers in training set
Top 0.6%
1.2%
20
iScience
1063 papers in training set
Top 22%
1.2%
21
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.2%
0.9%
22
Molecular Cancer
14 papers in training set
Top 0.7%
0.9%
23
Immunology
29 papers in training set
Top 0.8%
0.9%
24
Pharmaceuticals
33 papers in training set
Top 2%
0.8%
25
PLOS Pathogens
721 papers in training set
Top 8%
0.8%
26
Blood Advances
54 papers in training set
Top 1%
0.7%
27
Cancer Letters
32 papers in training set
Top 0.9%
0.7%
28
Molecular Cancer Therapeutics
33 papers in training set
Top 0.7%
0.7%
29
International Journal of Molecular Sciences
453 papers in training set
Top 18%
0.6%
30
JCI Insight
241 papers in training set
Top 8%
0.6%